• Ortho-ATI™ tendon regeneration treatment long-term data published in prestigious AJSM
• Patients’ pain decreased significantly and grip strength improved on average by 207% at 3-5 years
• Ortho-ATI™ shown to be a disease modifying treatment providing sustained pain relief and significant functional improvements
Perth, Australia; 30 April 2015: Regenerative medicine company Orthocell Limited has today announced its long-term study into its Ortho-ATITM treatment for chronic tennis elbow was published in the latest edition of the prestigious American Journal of Sports Medicine (AJSM).
The publication provides evidence of the durability and long term positive effect of Orthocell’s Ortho-ATI™ tendon regeneration treatment for degenerate tendon injuries. The results showed grip strength scores of patients suffering from a severe form of tennis elbow, also called chronic lateral epicondylitis, improved by an average 84% at one year after treatment and 207% at an average of 4.5 years after they underwent the minimally invasive injection procedure.
“The results are a significant step forward in the delivery of an effective stem cell treatment for degenerate tendons and is one of the longest follow up studies in the field of cellular therapies,” Orthocell Managing Director Paul Anderson said.
“This data supports our mission of regenerating mobility for patients with tendon injuries and the ageing population.”
Patients with severe chronic resistant lateral epicondylitis (tennis elbow) who had failed all other treatment options including corticosteroids and remedial physiotherapy, received a single injection of their own healthy tendon cells that were manufactured in Orthocell’s Therapeutic Goods Admiration (TGA) licensed facility in Australia. Patients demonstrated significant improvements in pain, clinical function and structural repair with an average follow up of 4.5 years.
Tennis elbow is a painful condition caused by damage and degeneration of tendons in the elbow because of overuse. It is a condition that seriously affects between 1-3% of the population and according to Transparency Market Research (2014), is responsible for more than US$750 million in annual surgery expenditure.
“Ortho-ATI™ has proven itself to be a durable technology and cost effective treatment and establishes Orthocell as leaders the field of regenerative musculoskeletal medicine,” Mr Anderson said.
Ortho-ATI™ is available in Australia, New Zealand and Hong Kong for patients who have failed conservative treatment options such as corticosteroid injections and exercise programmes and have on going symptoms.
For more information, please contact:
General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our aging population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to augment, repair, replace or regenerate areas which have been damaged by disease, injury or the ageing process. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approval.
Help employers find you! Check out all the jobs and post your resume.
